Medicine

Bristol Myers Squibb will cut 6% of its workforce in a restructuring meant to save $1.5 billion in costs by the end of next year.  The layoffs will affect some…

Dive Brief: The Food and Drug Administration on Friday approved a new gene therapy for hemophilia, clearing Pfizer’s Beqvez for certain people with the less common “B” form of the…

Dive Brief: U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8 billion, as biosimilar copycats put pressure on AbbVie’s top-selling drug,…

Dive Brief: BioMarin on Wednesday said it’s wrapped up a pipeline review and will stop investing in four experimental therapies because they don’t meet its threshold for patient impact and…

AstraZeneca’s revenue and profits grew at a rapid clip over the first three months of the year, beating Wall Street expectations as use of the British drugmaker’s flagship cancer drugs…

Investors who had hoped Biogen would do another flashy deal this year may not want to hold their breath, as the biotechnology company signaled that, at least for the time…

Moderna is betting big on bespoke artificial intelligence assistants. The biotechnology company on Wednesday said it has expanded a partnership with OpenAI, the buzzy creator of ChatGPT, to give its…

Sales of Novartis drugs for heart failure, psoriasis and multiple sclerosis were stronger over the first three months of the year than anticipated, helping the Swiss pharmaceutical company report first…

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick…

Dive Brief: Eli Lilly on Monday said it will acquire a drug plant from Nexus Pharmaceuticals to expand its manufacturing capacity for injectable medicines. Located in Pleasant Prairie, Wisconsin, the…

Dive Brief: French pharmaceutical company Ipsen will work with privately held biotechnology company Skyhawk Therapeutics to make small molecule drugs that modify RNA. Through a collaboration announced Monday, Ipsen and…

Dive Brief: Uwe Schoenbeck, a biotech veteran who most recently was chief scientific officer at Pfizer’s innovation division, has joined Canaan Partners as a venture partner, the investment firm announced…

Dive Brief: Alvotech and Teva on Tuesday won Food and Drug Administration approval for Selarsdi, the second biosimilar poised to challenge Johnson & Johnson’s blockbuster psoriasis drug, Stelara. The FDA…

Dive Brief: Metsera, a richly funded biotechnology startup, launched Thursday with a portfolio of weight loss drugs the company claims could eventually compete with market-leading medicines from Novo Nordisk and…

Cerevel Therapeutics, a biotechnology company in the midst of being acquired by AbbVie, on Thursday said a Parkinson’s disease treatment it’s developing succeeded in a late-stage clinical trial. The treatment,…

The Food and Drug Administration has made a medicine from Roche the first specifically available for early treatment of lung tumors driven by a well-known cancer gene. On Thursday, the…

Dive Brief: Alvotech and U.S. commercial partner Teva have signed a “long-term agreement” with an unspecified company to boost access to their biosimilar version of AbbVie’s blockbuster drug Humira, Alvotech…

Vertex Pharmaceuticals is vying for approval of an experimental and closely watched painkiller that could become an alternative to addictive opioids like Vicodin. On Thursday, the biotechnology company said the…

Dive Brief: 23andMe CEO Anne Wojcicki plans to take the DNA testing company private, according to a Wednesday filing with the U.S. Securities and Exchange Commission.  Wojcicki currently owns more…

An experimental drug designed to improve brain function in people with nerve-degrading disorders has failed a mid-stage study that tested it against Parkinson’s disease. The trial enrolled almost 90 participants,…

Fresh clinical trial results for Eli Lilly’s drug Zepbound point to a new use for the weight loss medicine in treating a common sleep disorder, adding to evidence the benefits…

An antipsychotic drug from Intra-Cellular Therapies appears to also work as an add-on therapy for depression, according to clinical trial results the New York-based biotechnology company released Tuesday. The large trial…

Dive Brief: Sales of Johnson & Johnson’s multiple myeloma medicine Tecvayli more than doubled in the first quarter versus the same period last year, boosting the pharmaceutical company’s oncology business…

Shares of Neumora Therapeutics fell Monday after the company disclosed a small clinical trial testing one of its experimental medicines for schizophrenia has been halted by the Food and Drug…

Dive Brief: Roche’s new dual-acting blood cancer drug Columvi combined with chemotherapy helped people with a type of lymphoma live longer than people given Rituxan and chemo, the company said…

When Katherine Wisner began studying postpartum mental health in the 1980s, the field barely existed. Relatively little research was focused on psychiatric illness related to pregnancy, and postpartum depression wasn’t…

Dive Brief: Biotechnology company Rallybio is partnering with Johnson & Johnson, announcing a collaboration Wednesday to develop new treatments for a rare disorder known as fetal and neonatal alloimmune thrombocytopenia,…

Dive Brief: Genentech, the research subsidiary of Swiss pharmaceutical giant Roche, has decided to cut short a partnership focused on cell therapies for cancer. Forged in September 2021, the deal…

Initial public offerings by biotechnology companies reached pre-pandemic levels during the first quarter, with nine drugmakers collectively raising more than $1.3 billion, according to BioPharma Dive data. The sum is…

Dive Brief: Novo Nordisk and Eli Lilly drugs to treat diabetes and obesity have no “causal association” with suicidal thoughts or incidents of suicide or self-harm, Europe’s health regulator said…

The U.S. Department of Justice on Wednesday accused Regeneron of defrauding Medicare by knowingly inflating the average sales price for its top-selling eye drug Eylea. In a lawsuit filed in…

Dive Brief: Biotechnology company Century Therapeutics is expanding its autoimmune disease research with a pair of deals that will hand it $60 million in new funding and technology from a…

Dive Brief: Vertex Pharmaceuticals on Wednesday said it would buy biotechnology company Alpine Immune Sciences and its experimental kidney disease drug for $65 per share, or approximately $4.9 billion in…

Dive Brief: Novartis will pause enrollment in certain clinical trials of its breast cancer drug Kisqali in order to meet regulators’ concerns around impurities related to nitrosamines, the company said…

Dive Brief: Pfizer on Tuesday said it plans to ask regulators to broaden the approval of its vaccine for respiratory syncytial virus, or RSV, after the shot met the goal…

Hoping to repeat a recent success story, the biotechnology startup creator PureTech Health has launched a new company aimed at developing psychiatric medicines. Seaport Therapeutics officially debuted Tuesday with $100…

Private funding for biotechnology startups rose during the first three months of the year, suggesting some of the sector’s momentum has translated to stepped-up investment in young drugmakers. Twenty-six companies…

Dive Brief: Novo Nordisk’s weight loss drug Wegovy helped people with obesity, diabetes and heart failure have fewer cardiovascular symptoms like fatigue and breathlessness, according to clinical trial results detailed…

Dive Brief: Diagonal Therapeutics, a biotechnology startup focused on creating antibodies that activate, rather than block, their targets, emerged from stealth Wednesday with $128 million in funding. Created by industry…

Amylyx Pharmaceuticals is pulling from market one of the few approved treatments for ALS. Rarely do drugmakers voluntarily withdraw products. In Amylyx’s case, the decision comes just weeks after a…

Dive Brief: Swiss drugmaker Basilea Pharmaceutica on Wednesday won Food and Drug Administration approval for its drug Zevtera in a step that could help address the critical need for new…

Johnson & Johnson has agreed to acquire Shockwave Medical for approximately $13.1 billion, the companies announced Friday morning. The deal values Shockwave at $335 per share. J&J said in a…

Dive Brief: The Food and Drug Administration has cleared Bristol Myers Squibb and 2seventy Bio’s multiple myeloma cell therapy for earlier use treating the blood cancer, approving the CAR-T medicine…

Dive Brief: Boehringer Ingelheim is laying off staff in response to sluggish adoption of its Humira biosimilar Cyltezo, a company spokesperson confirmed to BioPharma Dive. Stat first reported the news Thursday.…

Contineum Therapeutics has raised $110 million in an initial public offering, the biotechnology industry’s 10th of the year, to advance a group of drugs it’s developing for neurological and inflammatory…

Dive Brief: Merck & Co. has begun a large clinical trial testing an experimental cancer drug it’s developing for tumors that harbor mutations in a tough-to-target gene called KRAS, The…

Dive Brief: Genmab said Wednesday it’s agreed to pay $1.8 billion for ProfoundBio, gaining access to the biotechnology startup’s technology for developing antibody-drug conjugates, or ADCs. ProfoundBio’s portfolio includes Rina-S,…

Dive Brief: A third biotechnology company from the startup creator Paragon Therapeutics is heading to the public markets. Paragon’s Oruka Therapeutics, which is developing biologic drugs for chronic skin diseases,…

Dive Brief: Acorda Therapeutics has filed for bankruptcy and, on Monday, announced it has reached an agreement to sell essentially all its assets to another drugmaker. Acorda said it chose…

Dive Brief: An experimental drug being developed by a subsidiary of Roivant Sciences succeeded in a Phase 2 trial testing it for a type of inflammatory eye condition called non-infectious…

The year started well for the biotechnology industry. Steady dealmaking coupled with a rebound in initial public offerings helped lift investor confidence and, with it, drugmaker stocks. While that optimism…

Dive Brief: Vertex Pharmaceuticals on Monday said it will advance an experimental kidney disease drug into Phase 3 testing and expand enrollment to include adolescents between the ages of 10…

The Food and Drug Administration on Tuesday approved a new Merck & Co. drug to treat pulmonary arterial hypertension. Called Winrevair, the drug is the first treatment that targets the…

A large clinical trial has found that a drug commonly used by patients with ALS is not effective at treating the nerve-destroying disease. The trial enrolled more than 300 patients…

Two years after Art Krieg sold his last biotechnology company to Regeneron Pharmaceuticals, the scientific entrepreneur and industry veteran is quietly building a new drug startup. Called Zola Therapeutics, the…

When the Food and Drug Administration expanded approval of Novo Nordisk’s weight loss medicine Wegovy to also protect heart health, the Danish drug giant had already made a pipeline commitment…

Dive Brief: Bristol Myers Squibb’s cancer pill Krazati helped people with a certain kind of non-small cell lung cancer live longer without their disease progressing and shrank tumors at a…

Dive Brief: Gilead Sciences will pay $30 million and invest another $13.5 million in Xilio Therapeutics to access an experimental immunotherapy drug the Massachusetts biotechnology company is developing for cancer.…

Dive Brief: The Food and Drug Administration has approved Akebia Therapeutics’ blood-boosting pill Vafseo for people with anemia from chronic kidney disease, the company said Wednesday, reversing a rejection the agency…

Dive Brief: Boundless Bio, a cancer drug developer backed by Bayer and Arch Venture Partners, has raised $100 million in the biotechnology industry’s ninth initial public offering this year. The…

Dive Brief: Blackstone Life Sciences will invest as much as $750 million on influenza vaccine research and development by Moderna, announcing Wednesday a private funding deal that gives the private…

The Supreme Court on Tuesday heard legal arguments in a high-profile case involving the Food and Drug Administration’s expanded approval of the abortion pill mifepristone, nearly two years after the…

Dive Brief: A dual-acting weight loss pill from Viking Therapeutics helped people with obesity lose up to 5% of their body weight over four weeks in a small trial designed…

An experimental drug from Axsome Therapeutics was successful in a late-stage clinical trial evaluating it as a treatment for narcolepsy symptoms. The trial found Axsome’s drug to be fast-acting and…

Dive Brief: Abbvie is expanding its pipeline of inflammatory disease drugs, announcing Monday a small deal to acquire biotechnology company Landos Biopharma. Per the deal, Abbvie will buy Landos for…

Capstan Therapeutics, a biotechnology startup developing medicines that reprogram cells inside the body, has raised another $175 million to bring its first prospect into clinical testing.  The high-profile startup, formed…

The executives behind autoimmune drug developer Prometheus Biosciences are back, armed with more than $400 million to launch their latest venture, a biotechnology startup known as Mirador Therapeutics. Based in…

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Bayer CEO Bill Anderson’s structural overhaul is now reaching the…

Dive Brief: Thermo Fisher Scientific said Wednesday that it has partnered with Bayer to develop companion diagnostic assays for the drugmaker’s precision cancer therapies.  Thermo Fisher will develop the next-generation…

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Medicare will cover the costs of Novo Nordisk’s obesity drug Wegovy for…

Dive Brief: The Food and Drug Administration on Thursday approved a first-of-its-kind drug for Duchenne muscular dystrophy, clearing Duvyzat, a medicine developed by Italian pharmaceutical company Italfarmaco and to be…

Cancer immunotherapy developer NextCure is laying off 37% of its staff and streamlining its research plans, the company said Thursday.  Alongside its 2023 earnings, the biotech revealed that it is…

An autoimmune disease drug from Roche and Chugai Pharmaceutical hit its main goal in a closely watched trial, but the results of the study, in a condition called myasthenia gravis,…

Dive Brief: Orchard Therapeutics said Wednesday it will offer a new gene therapy to children with a rare, devastating disease at a record-setting wholesale price of $4.25 million.  The therapy,…

A young biotechnology company plans to move an experimental medicine for a rare eye disease into late-stage testing after results from a small study signaled that it is generally safe…

Dive Brief: Orchard Therapeutics on Monday won Food and Drug Administration approval for the first gene therapy to treat a deadly and devastating rare disease in children called metachromatic leukodystrophy.…

Dive Brief: Bayer on Tuesday said it plans to seek regulatory approval of a drug for symptoms of menopause following positive results from a third Phase 3 trial.  The drug,…

Ask a healthcare professional (HCP), and chances are good that they’d like an easy way to reach out to biopharma field reps. In-person meetings are still the gold standard, but…

Gene therapy developer Bluebird bio has raised a large debt financing in a bid to extend its cash runway for another year.  The company on Monday announced that it’s secured…

Dive Brief: Tubulis, a German biotechnology startup developing antibody-drug conjugates, brought in €128 million, or about $140 million, to bring its first prospects into clinical testing.  The startup, which is…

Asgard Therapeutics has become the latest emerging developer of “in vivo” cell therapies to attract the attention of large drugmakers. The Swedish biotechnology startup on Thursday raised 30 million euros,…

Dive Brief: AstraZeneca is bolstering its rare disease division with the purchase of Amolyt Pharma, an endocrine disease specialist backed by Novo Holdings. Under the deal announced Thursday, AstraZeneca will…

The first drug for metabolic dysfunction-associated steatohepatitis will cost $47,400 per year, its developer, Madrigal Pharmaceuticals, said Thursday.  Madrigal revealed the price and launch plan for Rezdiffra on a conference…

Advisers to the Food and Drug Administration have endorsed the use of two cellular medicines for multiple myeloma earlier in a patient’s disease, overlooking safety concerns raised by agency reviewers…

Dive Brief: For the first time, the Food and Drug Administration has approved a cell therapy for hard-to-treat forms of two blood cancers. Sold as Breyanzi, the therapy is now…

The Food and Drug Administration has approved the first medicine for a common liver disease that’s been a top target of drugmakers over the last decade. The drug, known as…

Dive Brief: The Biotechnology Innovation Organization on Wednesday backed legislation aiming to limit the industry’s association with Chinese life sciences companies that have alleged ties to the Chinese government, including…

Dive Brief: Merck on Wednesday announced plans to start clinical trials testing a newer version of its vaccine for human papillomavirus, or HPV, as well as a different regimen of…

Two cellular medicines for multiple myeloma were associated with an increased risk of early death in clinical testing, raising questions about whether they should be earlier in a patient’s disease,…

For Rick Bedlack, director of the ALS clinic at Duke University, tough times come with the job. He and his team treat about 500 people with the rare, fatal disorder…

Allogene Therapeutics is turning to gene editing startup Arbor Biotechnologies for help developing “off-the-shelf” cell therapies for autoimmune diseases, the companies said Tuesday.  Allogene has been a longtime leader in…

Dive Brief: Roche’s experimental Alzheimer’s disease drug trontinemab showed “best-in-class” potential based on its ability to quickly clear clumps of amyloid protein from the brains of patients enrolled in a…

In 2020, a small clinical trial had a big impact. The study evaluated whether a drug from a young and relatively unknown biotechnology company could help people with amyotrophic lateral…

Boundless Bio, an oncology startup backed by Bayer and Arch Venture Partners, on Wednesday became the first biotechnology company to file for an initial public offering since late January.  The…

Dive Brief: An experimental pill developed by Novo Nordisk helped obese people lose 13% of their body weight after three months of treatment in a small clinical trial, the company…

A large clinical trial meant to confirm the benefits of a new ALS medication has instead failed, dealing a major blow to the therapy’s developer as well as patients who…

Dive Brief: The Food and Drug Administration is delaying an approval decision on Eli Lilly’s experimental medicine for Alzheimer’s disease so it can hold an advisory committee meeting to more…

The Food and Drug Administration has expanded the label for Novo Nordisk’s fast-selling weight loss drug Wegovy following study results that proved the medicine can protect heart health.  The agency…

Cigna is moving to limit how much health insurance providers and employers have to pay for pricey and in-demand obesity medications. The insurer plans to cap annual price increases for…

A Boston-based biotechnology company on Thursday said its most advanced drug showed positive effects in a clinical trial of Parkinson’s disease patients, results that at least one analyst believes could…

Dive Brief: President Biden is taking on a bipartisan bogeyman ahead of a critical State of the Union speech, targeting the pharmaceutical industry and saying he will work to expand…

Dive Brief: Barcelona-based venture capital firm Invivo Partners is preparing to close an expected fund of 100 million euros, or $109 million, the third since its formation. In a LinkedIn…

Dive Brief: Sionna Therapeutics, a Waltham, Massachusetts biotechnology startup, announced Wednesday it raised a $182 million Series C round to advance a group of experimental drugs for cystic fibrosis.   Founded…

Dive Brief: An experimental RNA-based medicine developed by Alnylam Pharmaceuticals, when added to standard drugs, helped lower blood pressure significantly more than a placebo in a Phase 2 trial of…

Dive Brief: Apogee Therapeutics plans to start a Phase 2 study of an experimental eczema treatment in the first half of 2024 after revealing earlier-than-expected positive data from an initial…

Investors have poured $62 million into a biotechnology startup developing a drug to treat chronic cough. Nocion Therapeutics, headquartered in Watertown, Massachusetts, announced Monday it completed a Series B fundraise…

Dive Brief: The effects of an experimental medicine for a common liver disease strengthened with time in a clinical trial, giving the drug’s developer, Akero Therapeutics, a chance to rebound…

Dive Brief: Abingworth, a venture capital group owned by Carlyle, will invest as much as $210 million to help Gilead Sciences further expand the approved usage of the cancer drug…

A good track record can be valuable in the uncertain and risky world of drug development. For a group of life sciences investors, it’s worth at least some part of…

Advisers to the Centers for Disease Control and Prevention are weighing updates to their recommendation older adults get vaccinated for respiratory syncytial virus, discussing changes at a meeting Thursday that…

Dive Brief: Cancer drug developer FogPharma has raised $145 million in fresh funding, the company revealed Friday, announcing a Series E round that will give a financial boost to the…

Pfizer believes the answer to its sliding valuation lies in oncology.  The company, which is coming off one of the worst years in its history, unveiled on Thursday a new…

Gritstone Bio will lay off about 40% of its workforce after missing out on funding it expected to receive this quarter, the company said Thursday. Gritstone, a maker of vaccines…

Kenai Therapeutics, a San Diego-based biotechnology company, has raised $82 million to support its work developing cell therapies for nervous system disorders. Cure Ventures, a new venture capital firm founded…

Dive Brief: ObsEva, a women’s health drug developer, on Wednesday said it plans to wind down its business and let go of all its employees. The company notified the Swiss…

An Australian-based biotechnology company says a mid-stage clinical trial has shown that psilocybin, a psychedelic compound found in many mushroom species, helped people with generalized anxiety disorder. The trial recruited…

Ginkgo Bioworks has acquired a biotechnology startup co-founded by gene editing pioneer Feng Zhang, part of the cell engineering company’s plan to build up technologies that can help other companies…

Dive Brief: An experimental weight loss drug developed by Viking Therapeutics helped overweight and obese people lose up to 15% of their body weight after 13 weeks of treatment in…

Dive Brief: GSK said Monday that its oral antibiotic succeeded in a late-stage trial in gonorrhea, proving to be as effective as an existing treatment for the infection.  According to GSK,…

Dive Brief: The Food and Drug Administration on Saturday approved Alvotech and Teva Pharmaceuticals’ Simlandi, a biosimilar of the most popular version of AbbVie’s rheumatoid arthritis drug Humira. The drug,…

The creativity and expertise of the researchers, technicians and assistants working in healthcare and biopharmaceutical laboratories are critical for every investigation’s success. If a lab is to generate groundbreaking results,…

ORI Capital, the China- and U.S.-based venture investor behind the biotechnology sector’s largest initial public offering this year, has raised a new life sciences fund, the firm said Thursday. The…

Dive Brief: Novavax will pay as much as $475 million to settle a dispute with Gavi, the Vaccine Alliance over an advance purchase agreement for COVID-19 vaccines. The Gaithersburg, Maryland-based…

Dive Brief: Moderna shares rose by as much as 10% Thursday morning after the COVID-19 vaccine developer reported fourth quarter profit that beat Wall Street expectations of a net loss…

The Biden Administration, through the Advanced Research Projects Agency for Health, has committed to invest $100 million into women’s health research, First Lady Jill Biden announced Wednesday. The investment is…

Dive Brief: The European Medicine Agency’s main drug review committee on Friday supported expanding the approval of Johnson & Johnson and Legend Biotech’s cell therapy Carvykti for earlier treatment of…

Dive Brief: BioMarin Pharmaceutical is struggling to sell the first marketed gene therapy for the most common form of hemophilia, announcing on Thursday minimal revenue from the treatment, called Roctavian.…

Biotechnology startup Frontier Medicines has pulled in $80 million in new funding to support a targeted cancer drug the company thinks might address some of the limitations of medicines from…

Infectious disease drug developer Vir Biotechnology on Tuesday disclosed that chief medical officer Phil Pang is stepping down from his role to spend more time with his family. Pang will…

A new research paper offers the most thorough look yet at a study that sparked the drug industry’s recent experimentation with cell therapy for autoimmune diseases. The paper, which was…

Dive Brief: AstraZeneca’s targeted cancer therapy Tagrisso can now be used alongside chemotherapy to treat a common type of locally advanced or metastatic lung tumor, following a Food and Drug…

Dive Brief: Shares of Rapt Therapeutics fell sharply Tuesday after the company disclosed U.S. regulators ordered a halt of two studies testing a drug the biotechnology company is developing for…

Lisa Benincosa is senior vice president of clinical pharmacology strategy at the specialized Clinical Research Organization (CRO), Allucent. Here she discusses how she and her team leverage the power of…

Dive Brief: The Food and Drug Administration has approved a new regimen for pancreatic cancer, clearing Ipsen’s Onivyde to be used with chemotherapy in treating recently diagnosed metastatic tumors, the…

Dive Brief: Aurinia Pharmaceuticals will restructure its operations and give money back to shareholders after failing to find a buyer willing to take over the company. Investors can expect a…

Astellas Pharma is delving deeper into cell therapies for cancer, announcing Thursday a research deal to develop a pair of treatments with the help of Boston-based biotechnology startup Kelonia Therapeutics.…

Gilead Sciences is evaluating the future of a cancer drug acquired in a multibillion-dollar deal following a new setback the company reported late Thursday. In a statement, Gilead said it…

Dive Brief: The Food and Drug Administration will decide by June 21 whether to loosen the restrictions surrounding use of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, the company…

Dive Brief: An experimental drug being developed by Denali Therapeutics and partner Sanofi for ALS failed to meet its goal in a Phase 2 trial, the biotechnology company disclosed Thursday…

Intellia Therapeutics will work with a private biotechnology company to develop genetic medicines for cystic fibrosis, with an initial focus on people who have limited or no available treatment options.…

Dive Brief: Alnylam Pharmaceuticals is delaying the readout of a closely watched Phase 3 trial in the heart disease transthyretin amyloidosis with cardiomyopathy, revealing Thursday changes to the study’s plan.…

Dive Brief: Firefly Bio, a startup working to develop a new kind of cancer medicine, announced Thursday it had raised $94 million in venture funding. The California-based company is putting…

Sage Therapeutics said its new medicine, the first oral treatment for postpartum depression, is off to an encouraging start, with signs of demand from prescribing doctors. Sage and partner Biogen…

A little over four years ago, biotechnology giant Amgen retreated from neuroscience research, halting much of its work developing treatments for diseases of the brain and trimming associated staff. Amgen’s…

Dive Brief: Biotechnology startup BioAge Labs has raised $170 million to support an experimental pill it plans to test alongside popular weight-loss drugs like Wegovy and Zepbound, the company announced…

As the venture arm of Alphabet, GV can be thought of as a technology investor. But over the last 15 years, the firm has become one of the biotechnology sector's…

Six biotechnology startups are merging into a new skin drug developer called Alys Pharmaceuticals, which launched on Monday with $100 million from European life sciences investment firm Medicxi. Alys was…

As life sciences and pharma services companies forge ahead in 2024, they find themselves at a critical juncture―realizing unparalleled opportunities while managing market challenges. Many leaders have or are asking…

Amgen is a global pharmaceutical company worth more than $160 billion. Nine of its marketed medicines are blockbuster products by annual sales. Yet, on a Tuesday conference call discussing Amgen’s…

BioNTech will pay $50 million and make a $200 million investment in Autolus Therapeutics as the company most famous for its COVID-19 vaccine boosts its cell therapy capabilities. Per deal…

Dive Brief: Neurona Therapeutics, a San Francisco-based biotechnology company, has raised another $120 million to fuel its research into cell therapies for brain diseases. Neurona plans to use the money…

Biotechnology initial public offerings are showing sustained signs of life for the first time in two years, and Kyverna Therapeutics’ larger-than-expected raise on Wednesday is the latest example.  The company,…

Takeda Pharmaceutical plans to quickly begin late-stage testing of an experimental drug for narcolepsy, which, if successful, could help the company enter what Wall Street analysts see as a multibillion-dollar…

Dive Brief: Metagenomi, a gene editing startup spun out of research at the University of California, Berkeley, brought in about $93.8 million in the biotechnology sector’s sixth initial public offering…

The CEOs of three major drugmakers defended the prices they charge U.S. patients in a Senate committee hearing Thursday, claiming Americans gain access to cutting-edge medicines months or years earlier…

Dive Brief: Kyverna Therapeutics raised $319 million in a larger-than-expected initial public offering Thursday, adding to an early, but notable, upturn in investor demand for new biotech stock issuances. The…

Dive Brief: BridgeBio Pharma is selling partial rights to an experimental drug for a common form of dwarfism to Japanese pharmaceutical company Kyowa Kirin, the companies announced Wednesday. Per deal…

Dive Brief: Scion Life Sciences on Wednesday made its debut as a venture firm, announcing the close of a $310 million fund to invest in new biotechnology startups. Led by…

Sales of Eli Lilly’s diabetes drug Mounjaro exceeded $5 billion in 2023, its first full year on the market, the company said Tuesday, in the latest sign of surging demand…

To hear venture capitalist Alex Morgan tell it, investors shouldn’t be in the business of predicting trends. “There's often a public perception that we're in the prediction game,” said Morgan,…

Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk, will buy contract manufacturer Catalent for $16.5 billion in a take-private deal the companies announced Monday. In a related transaction,…

In 2021, the Food and Drug Administration for the first time approved a medicine meant to slow the progression of Alzheimer’s disease. Developed by partners Biogen and Eisai, the medicine,…

Dive Brief: The gene therapy company Avrobio agreed to a reverse merger with startup Tectonic Therapeutic after years of struggling with clinical setbacks and a tough financing market for the…

Roche is reshaping its early-stage pipeline of experimental drugs, jettisoning eight drug candidates in neurological conditions and oncology as it makes room for a set of obesity treatments it gained…

Dive Brief: Protagonist Therapeutics, a biotechnology company focused on peptide drugs, is teaming up with Takeda Pharmaceutical on an experimental, injectable medicine for a rare blood disorder. Per terms of…

Merck & Co. plans to continue seeking out multibillion-dollar biotechnology deals to supplement its own drug research as it prepares for its dominant cancer immunotherapy Keytruda to lose patent protection…

Arch Venture Partners, one of the biotechnology sector’s most prolific company creators, is raising a new $3 billion fund, according to a regulatory filing. The fund, which would be Arch’s…

Another biotechnology company has hit Wall Street via an initial public offering, the third to do so this year in an uptick of IPO activity that suggests rebounding investor interest…

Nestlé veteran François-Xavier Roger will succeed Sanofi chief financial officer Jean-Baptiste Chasseloup de Chatillon on April 1, the French pharmaceutical company said Thursday alongside fourth quarter earnings. Chatillon will be…

The U.S. government will test whether centrally coordinating insurance coverage can help people with sickle cell disease access expensive new gene therapies for the inherited blood condition. Two such treatments…

GSK on Wednesday reported higher-than-expected sales of its RSV vaccine Arexvy, providing further evidence of the product’s strong uptake. The shot brought in 1.2 billion pounds, or about $1.5 billion,…

Dive Brief: Biotechnology startup Cour Pharmaceuticals has raised $105 million to advance a portfolio of medicines for autoimmune diseases. The startup’s funding was co-led by Alpha Wave Ventures and Lumira…

Dive Brief: Gilead has bought a bigger stake in cancer drug developer Arcus Biosciences, announcing Monday it will spend $320 million to own 33% of the company and help speed…

A closely watched non-opioid painkiller succeeded in two large clinical trials, raising hopes the drug might offer an alternative to powerful but addictive medicines like OxyContin or Vicodin. Results showed…

Dive Brief: An experimental, under-the-skin shot of Bristol Myers Squibb’s immunotherapy Opdivo appeared to work similarly to the approved, intravenous version of the drug, shrinking kidney tumors at an equivalent…

Johnson & Johnson CEO Joaquin Duato sold 2023 as a “remarkable year” on an earnings call with investors Tuesday. But the pharmaceutical giant faces looming difficulties that hang over its…

Dive Brief: Novo Nordisk is adding yet another prospect to its obesity drug pipeline, this time from a biotech company spun out of Harvard University and Zurich University. ·  EraCal…

After a rocky year that featured a restructuring, job cuts and the resignation of its CFO, BenevolentAI is looking to the future by tapping a Bayer veteran as its new…

Radiopharmaceutical drugmaker RayzeBio drew interest from two other large drugmakers before agreeing to a $4.1 billion buyout by Bristol Myers Squibb, newly published documents show. The companies, which were not…

European authorities are set to rescind the approval of a Duchenne muscular dystrophy drug that’s been on the market there for nearly a decade following evidence the medicine, Translarna, doesn’t…

Dive Brief: Bristol Myers Squibb’s cell therapy for multiple myeloma, Abecma, should be approved for use in patients whose disease has progressed following two standard treatments, the European Medicines Agency’s…

Dive Brief: ArriVent Biopharma is the second biotechnology company to go public this year, raising $175 million in an initial public offering Thursday that will support development of an experimental…

The Food and Drug Administration this week convened a group of experts to discuss ways to develop new drugs for preventing spontaneous early births, a major health concern for which…

Cancer drug developer CG Oncology has raised $380 million in an initial public offering than was larger than it expected, a positive sign for a sector that’s struggled to generate demand…

An 11-year-old boy who was born deaf can hear after receiving an experimental gene therapy, developer Eli Lilly reported on Tuesday. The boy, identified as Aissam Dam by The New…

Sanofi on Tuesday said it will acquire San Diego biotechnology company Inhibrx in a complex deal that could be worth up to $2.2 billion. The focus of the deal is…

Dive Brief: The makers of CAR-T cell therapies will need to warn about the risk of new blood cancer, the Food and Drug Administration said, following a review of reports…

Dive Brief: Coherus Biosciences on Monday said it has agreed to sell its approved biosimilar Cimerli, along with supporting staff, to Sandoz for $170 million in cash. The deal will…

Dive Brief: Gilead Sciences on Monday said its cancer drug Trodelvy missed the main goal of a Phase 3 trial in lung cancer, failing to help keep patients alive longer…

As part of a makeover promised last year, Bayer is beginning a process of staff reductions that aims to slice through the bureaucracy CEO Bill Anderson blames for the company’s…

BridgeBio Pharma has agreed to sell future royalties on an experimental rare disease drug in exchange for $500 million if the medicine, called acoramidis, receives Food and Drug Administration approval.…

Five years ago this month, Takeda Pharmaceuticals completed a $62 billion acquisition of Shire — one of the largest deals in pharmaceutical industry history. The anniversary has resurfaced scrutiny over…

Biotechnology company Ikena Oncology on Thursday said it would lay off staff and reallocate resources toward two experimental cancer drugs. The oncology company is prioritizing the two candidates, dubbed IK-930…

A Congressional committee may subpoena the CEOs of Johnson & Johnson and Merck & Co. to testify about the differences between the costs of their drugs in the U.S. compared…

A radiopharmaceutical drug from Novartis kept a rare type of neuroendocrine cancer at bay for longer than did standard therapy, according to detailed clinical trial results unveiled by the Swiss…

Jaguar Gene Therapy is spinning out part of its business to handle the specialized work of manufacturing cell and gene therapies, launching Wednesday a new company called Advanced Medicine Partners. …

Mirae Asset Capital Life Science, a new venture capital fund, launched on Thursday, joining several other new firms that have recently emerged with plans to invest in drug startups. The…

Dive Brief: Kyverna Therapeutics on Tuesday revealed plans to go public, testing the waters in a biotechnology market that hasn’t fully recovered from a downturn that started in 2021. The…

Dive Brief: Massachusetts-based startup Comanche BioPharma has raised $75 million in new venture funding to advance an experimental treatment targeting a cause of the pregnancy-related condition preeclampsia. Preeclampsia involves sudden…